Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors
"NTRK fusion-positive tumors represent a significant therapeutic challenge, particularly in the setting of acquired resistance to existing TRK tyrosine kinase inhibitors (TKIs)," said Dr. Rafael Amado, M.D., President, Head of Global Research and Development at Zai Lab. "There are no approved treatments for NTRK-positive cancers for both TKI-naïve and TKI-pretreated patients in China. Repotrectinib has the potential to become a next-generation TKI that can be used across a broad range of NTRK fusion-positive solid tumors in both settings."
In February 2025, China's NMPA granted priority review to repotrectinib for the treatment of adult patients with advanced solid tumors that have an NTRK gene fusion.
About Repotrectinib
Repotrectinib is a next-generation tyrosine kinase inhibitor targeting the ROS1 and NTRK oncogenic drivers. Patients with solid tumors, including NSCLC, harboring ROS1 and NTRK gene fusions treated with approved targeted therapies often develop resistance mutations that limit binding of these drugs to their target. Ultimately, this leads to shortened duration of response and tumor progression. Repotrectinib is the first next-generation ROS1 and TRK TKI uniquely designed to improve durability of benefit, including in the brain, and to address acquired resistance.
In June 2024, AUGTYRO (repotrectinib) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a NTRK gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy.
In May 2024, AUGTYRO was approved by the NMPA for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small-cell lung cancer (NSCLC). It was approved by the FDA for this indication in November 2023.
Zai Lab has an exclusive license agreement with Turning Point Therapeutics, Inc. (a Bristol Myers Squibb company) to develop and commercialize AUGTYRO in Greater China (mainland China, Hong Kong, Taiwan, and Macau, collectively).
About NTRK-Positive Solid Tumors
NTRK-positive advanced malignancies are life-threatening with poor prognoses and represent an area of significant unmet medical need in adult and pediatric patients. Existing targeted therapies have demonstrated clinical benefits but are limited by the duration of response due to the emergence of acquired resistance mutations.1 In China, there was no approved treatment option for NTRK-positive cancers that was studied in both TKI-naïve and TKI-pretreated patients across solid tumors.
1 Harada G, Santini FC, Wilhelm C, Drilon A, et al. NTRK fusions in lung cancer: From biology to therapy. Lung Cancer. 2021;161:108-113.
About Zai Lab
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health.
For additional information about Zai Lab, please visit www.zailaboratory.com or follow us at https://x.com/ZaiLab_Global.
Zai Lab Forward-Looking Statements
This press release contains forward-looking statements relating to our future expectations, plans, and prospects, including, without limitation, statements relating to our prospects and plans for developing and commercializing repotrectinib in Greater China, the potential benefits of repotrectinib, and the potential treatment of NTRK-positive solid tumors. These forward-looking statements may contain words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "plan," "possible," "potential," "will," "would," and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact or guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products, (2) our ability to obtain funding for our operations and business decisions, (3) the results of our clinical and pre-clinical development of our product candidates, (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates, (5) risks related to doing business in China, and (6) other factors identified in our most recent annual and quarterly reports and in other reports we have filed with the U.S. Securities and Exchange Commission. We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Our SEC filings can be found on our website at www.zailaboratory.com and the SEC's website at www.sec.gov.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250421607809/en/
Contacts
For more information, please contact:Investor Relations: Christine Chiou / Lina Zhang+1 (917) 886-6929 / +86 136 8257 6943christine.chiou1@zailaboratory.com / lina.zhang@zailaboratory.com Media: Shaun Maccoun / Xiaoyu Chen+1 (857) 270-8854 / +86 185 0015 5011shaun.maccoun@zailaboratory.com / xiaoyu.chen@zailaboratory.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Markets Tightens After FED's Statement and New Tariffs
The US President had announced a number of new levies, including 10% global minimum and 15% for countries having trade surplus with the US. The US stocks have corrected from peaks as a result, driving S&P 500 and Nasdaq down for more than 1% from respective peaks. The overall macro sentiment shifts towards the tighter than expected monetary policy in September: after strong GDP data for the US, and Jerome Powell's press-conference, probabilities of interest rate in September shift towards 4.25 – 4.5 (60% of traders bet on this scenario according to FEDwatchtoll), which indicates the ambiguous situation around inflation. Yields of 30-year bonds in the US stabilize around achieved levels. The overall situation rather provides some pressure for cyclical assets and provokes capital to return to safe havens and rotation from speculative instruments back to the US dollar. Along with the US dollar, Japanese Yen also gains strength, as yields of 30-year bonds of Japan are kept at highs. Other 'safe havens', such as Swiss Franc, for example – don't show resilience in today's markets. The market entered the last summer month, August. It's usually considered a month with low volatility, but in case of unexpected geopolitical events, volatility may come earlier than in September. The US President Trump had announced a deadline for the Russia-Urkaine conflict for Aug 8 (end of next week) and pressured India and China to impose more tariffs in case of buying oil from Russia. This situation adds some uncertainty to the global energy markets, which we observe in the form of rising Crude oil. Crude Oil Crude oil climbs higher towards the peak of the Bollinger Bands: the upper border of a technical trading range. Oil is a momentum based instrument, i.e. it can continue the breakout, but given the main declining trend, the breakout probably has a small chance to be sustained. One may monitor for excessive breakout and spikes to the gray area (potential resistance area): in case the area is rejected, the mean-reversion trade with a price getting back to the range (and hitting $60 later within the year) might be a preferred option. Gold Gold is pushed down by the retreating US dollar and tight yields of 30-year treasury bonds, but the overall main trend still might be considered bullish. To continue climbing higher, however, it needs a trigger or shift in the narrative. The latter is unlikely, but it might find a technical trigger by a spike to the downside, as shown in the chart. If the responsive buying activity is visible, we might observe Gold getting back to the range. Commitment of Traders reports show commercial traders slowly unloading their positions, but the net position is still far from the bottom, so the uptrend might be intact. This article was originally posted on FX Empire More From FXEMPIRE: Spot Outliers Like ResMed Early with Money Flows Buy Like Big Money: Inflows Make Core & Main Soar Identify Outliers Like Palantir with Money Flows Strength for the Dollar After Higher Inflation Waiting Game: Fed Holds Steady, But Not Everyone's on Board France: Multi-year Budget Plan Supports Fiscal Outlook but Great Uncertainty Remains
Yahoo
29 minutes ago
- Yahoo
Axon (NASDAQ:AXON) Reports Upbeat Q2, Full-Year Outlook Slightly Exceeds Expectations
Self defense company AXON (NASDAQ:AXON) reported Q2 CY2025 results topping the market's revenue expectations , with sales up 32.8% year on year to $668.5 million. The company's full-year revenue guidance of $2.69 billion at the midpoint came in 1.2% above analysts' estimates. Its non-GAAP profit of $2.12 per share was 45% above analysts' consensus estimates. Is now the time to buy Axon? Find out in our full research report. Axon (AXON) Q2 CY2025 Highlights: Revenue: $668.5 million vs analyst estimates of $641 million (32.8% year-on-year growth, 4.3% beat) Adjusted EPS: $2.12 vs analyst estimates of $1.46 (45% beat) Adjusted EBITDA: $171.6 million vs analyst estimates of $160.7 million (25.7% margin, 6.8% beat) The company lifted its revenue guidance for the full year to $2.69 billion at the midpoint from $2.65 billion, a 1.5% increase EBITDA guidance for the full year is $675 million at the midpoint, in line with analyst expectations Operating Margin: -0.2%, down from 6.7% in the same quarter last year Free Cash Flow was -$114.7 million, down from $75.3 million in the same quarter last year Market Capitalization: $57.8 billion Company Overview Providing body cameras and tasers for first responders, AXON (NASDAQ:AXON) develops technology solutions and weapons products for military, law enforcement, and civilians. Revenue Growth A company's long-term performance is an indicator of its overall quality. Any business can have short-term success, but a top-tier one grows for years. Thankfully, Axon's 32.3% annualized revenue growth over the last five years was incredible. Its growth surpassed the average industrials company and shows its offerings resonate with customers, a great starting point for our analysis. We at StockStory place the most emphasis on long-term growth, but within industrials, a half-decade historical view may miss cycles, industry trends, or a company capitalizing on catalysts such as a new contract win or a successful product line. Axon's annualized revenue growth of 32.4% over the last two years aligns with its five-year trend, suggesting its demand was predictably strong. This quarter, Axon reported wonderful year-on-year revenue growth of 32.8%, and its $668.5 million of revenue exceeded Wall Street's estimates by 4.3%. Looking ahead, sell-side analysts expect revenue to grow 23.2% over the next 12 months, a deceleration versus the last two years. Despite the slowdown, this projection is healthy and indicates the market is baking in success for its products and services. Software is eating the world and there is virtually no industry left that has been untouched by it. That drives increasing demand for tools helping software developers do their jobs, whether it be monitoring critical cloud infrastructure, integrating audio and video functionality, or ensuring smooth content streaming. Click here to access a free report on our 3 favorite stocks to play this generational megatrend. Operating Margin Operating margin is an important measure of profitability as it shows the portion of revenue left after accounting for all core expenses – everything from the cost of goods sold to advertising and wages. It's also useful for comparing profitability across companies with different levels of debt and tax rates because it excludes interest and taxes. Axon was profitable over the last five years but held back by its large cost base. Its average operating margin of 1.8% was weak for an industrials business. On the plus side, Axon's operating margin rose by 17.7 percentage points over the last five years, as its sales growth gave it immense operating leverage. This quarter, Axon's breakeven margin was down 6.9 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Axon's EPS grew at an astounding 45.6% compounded annual growth rate over the last five years, higher than its 32.3% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded. Diving into Axon's quality of earnings can give us a better understanding of its performance. As we mentioned earlier, Axon's operating margin declined this quarter but expanded by 17.7 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its higher earnings; interest expenses and taxes can also affect EPS but don't tell us as much about a company's fundamentals. Like with revenue, we analyze EPS over a more recent period because it can provide insight into an emerging theme or development for the business. For Axon, its two-year annual EPS growth of 46.5% is similar to its five-year trend, implying strong and stable earnings power. In Q2, Axon reported adjusted EPS at $2.12, up from $1.20 in the same quarter last year. This print easily cleared analysts' estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Axon's full-year EPS of $7.06 to shrink by 6.1%. Key Takeaways from Axon's Q2 Results We were impressed that Axon beat analysts' revenue and EBITDA expectations this quarter. Looking ahead, full-year revenue guidance was raised, showing a strong demand environment. Zooming out, we think this was a good print with some key areas of upside. The stock traded up 4.1% to $773 immediately following the results. Sure, Axon had a solid quarter, but if we look at the bigger picture, is this stock a buy? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free.
Yahoo
31 minutes ago
- Yahoo
MercadoLibre (NASDAQ:MELI) Beats Q2 Sales Targets But Stock Drops
Latin American e-commerce and fintech company MercadoLibre (NASDAQ:MELI) announced better-than-expected revenue in Q2 CY2025, with sales up 33.8% year on year to $6.79 billion. Its GAAP profit of $10.31 per share was 13.3% below analysts' consensus estimates. Is now the time to buy MercadoLibre? Find out in our full research report. MercadoLibre (MELI) Q2 CY2025 Highlights: Revenue: $6.79 billion vs analyst estimates of $6.54 billion (33.8% year-on-year growth, 3.9% beat) EPS (GAAP): $10.31 vs analyst expectations of $11.89 (13.3% miss) Adjusted EBITDA: $1.02 billion vs analyst estimates of $1.06 billion (15.1% margin, 3.2% miss) "This compression [in margin] was primarily driven growth investments..., and marketing spend also increased to support our free shipping and Mercado Pago campaigns. We are confident these are the right investments to make for the benefit of our users and our ecosystem" Operating Margin: 12.2%, down from 14.3% in the same quarter last year Free Cash Flow Margin: 38.7%, up from 12.8% in the previous quarter Unique Active Buyers: 71 million, up 14.4 million year on year Market Capitalization: $121.5 billion Company Overview Originally started as an online auction platform, MercadoLibre (NASDAQ:MELI) is a one-stop e-commerce marketplace and fintech platform in Latin America. Revenue Growth A company's long-term sales performance can indicate its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Luckily, MercadoLibre's sales grew at an incredible 39.7% compounded annual growth rate over the last three years. Its growth surpassed the average consumer internet company and shows its offerings resonate with customers, a great starting point for our analysis. This quarter, MercadoLibre reported wonderful year-on-year revenue growth of 33.8%, and its $6.79 billion of revenue exceeded Wall Street's estimates by 3.9%. Looking ahead, sell-side analysts expect revenue to grow 27.8% over the next 12 months, a deceleration versus the last three years. Still, this projection is eye-popping given its scale and implies the market is baking in success for its products and services. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. Unique Active Buyers User Growth As an online marketplace, MercadoLibre generates revenue growth by increasing both the number of users on its platform and the average order size in dollars. Over the last two years, MercadoLibre's unique active buyers, a key performance metric for the company, increased by 20.8% annually to 71 million in the latest quarter. This growth rate is among the fastest of any consumer internet business and indicates its offerings have significant traction. In Q2, MercadoLibre added 14.4 million unique active buyers, leading to 25.4% year-on-year growth. The quarterly print was higher than its two-year result, suggesting its new initiatives are accelerating user growth. Revenue Per User Average revenue per user (ARPU) is a critical metric to track because it measures how much the company earns in transaction fees from each user. ARPU also gives us unique insights into a user's average order size and MercadoLibre's take rate, or "cut", on each order. MercadoLibre's ARPU growth has been exceptional over the last two years, averaging 15.4%. Its ability to increase monetization while growing its unique active buyers at an impressive rate reflects the strength of its platform, as its users are spending significantly more than last year. This quarter, MercadoLibre's ARPU clocked in at $95.63. It grew by 6.7% year on year, slower than its user growth. Key Takeaways from MercadoLibre's Q2 Results This compression [in margin] was primarily driven growth investments..., and marketing spend also increased to support our free shipping and Mercado Pago campaigns. We are confident these are the right investments to make for the benefit of our users and our ecosystem" Should you buy the stock or not? If you're making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it's free.
